Enlivex Therapeutics

Allocetra is the entire investment case at Enlivex Therapeutics, a clinical-stage biotech based in Nes-Ziona, Israel. The therapy reprograms macrophages, the immune cells that govern inflammation, and the company is testing it as an injection for knee osteoarthritis, where mid-stage trials reported large gains in pain and joint function across more than 250 patients. It is also studying versions for jaw-joint arthritis and for organ failure in sepsis. In 2026 the knee program won the FDA's Regenerative Medicine Advanced Therapy tag, a designation that can speed review. Like most single-asset developers, the stock trades on trial readouts rather than earnings, so any setback in the osteoarthritis data would hit hard. Enlivex has no approved products and funds itself through public markets, which makes cash runway as important to watch as the science.

On MyRWA, ENLV trades tokenized across 2 on-chain venues - see the listings below.